{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T06:31:33Z","timestamp":1778308293536,"version":"3.51.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1245\/s10434-023-14222-8","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T20:33:45Z","timestamp":1694205225000},"page":"8156-8165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of Successful Implementation of an Enhanced Recovery After Surgery Protocol for Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy"],"prefix":"10.1245","volume":"30","author":[{"given":"Beatrice J.","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany M.","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nova","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cedar","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byrne","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"issue":"8","key":"14222_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamaoncol.2021.0580","volume":"7","author":"RM Van Stein","year":"2021","unstructured":"Van Stein RM, Aalbers AGJ, Sonke GS, Van Driel WJ. Hyperthermic intraperitoneal chemotherapy for ovarian and colorectal cancer: a review. JAMA Oncol. 2021;7(8):1231. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0580.","journal-title":"JAMA Oncol."},{"issue":"6","key":"14222_CR2","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1245\/s10434-022-11441-3","volume":"29","author":"CD Valenzuela","year":"2022","unstructured":"Valenzuela CD, Levine EA, Mangieri CW, et al. Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for cancers with peritoneal metastasis: a 30-year institutional experience. Ann Surg Oncol. 2022;29(6):3436\u201345. https:\/\/doi.org\/10.1245\/s10434-022-11441-3.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"14222_CR3","doi-asserted-by":"publisher","first-page":"e206363","DOI":"10.1001\/jamasurg.2020.6363","volume":"156","author":"S Kusamura","year":"2021","unstructured":"Kusamura S, Barretta F, Yonemura Y, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 2021;156(3):e206363. https:\/\/doi.org\/10.1001\/jamasurg.2020.6363.","journal-title":"JAMA Surg."},{"issue":"23","key":"14222_CR4","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"PE Bonnot","year":"2019","unstructured":"Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37(23):2028\u201340. https:\/\/doi.org\/10.1200\/JCO.18.01688.","journal-title":"J Clin Oncol."},{"issue":"3","key":"14222_CR5","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ Van Driel","year":"2018","unstructured":"Van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1708618.","journal-title":"N Engl J Med."},{"issue":"6","key":"14222_CR6","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/IGC.0000000000001289","volume":"28","author":"TP D\u00edaz-Montes","year":"2018","unstructured":"D\u00edaz-Montes TP, El-Sharkawy F, Lynam S, et al. Efficacy of hyperthermic intraperitoneal chemotherapy and cytoreductive surgery in the treatment of recurrent uterine sarcoma. Int J Gynecol Cancer. 2018;28(6):1130\u20137. https:\/\/doi.org\/10.1097\/IGC.0000000000001289.","journal-title":"Int J Gynecol Cancer."},{"key":"14222_CR7","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.2147\/CMAR.S170300","volume":"11","author":"LM Enomoto","year":"2019","unstructured":"Enomoto LM, Shen P, Levine EA, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations. Cancer Manag Res. 2019;11:4231\u201341. https:\/\/doi.org\/10.2147\/CMAR.S170300.","journal-title":"Cancer Manag Res."},{"issue":"5","key":"14222_CR8","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.3390\/cancers15051402","volume":"15","author":"OG Huffman","year":"2023","unstructured":"Huffman OG, Chau DB, Dinicu AI, DeBernardo R, Reizes O. Mechanistic insights on hyperthermic intraperitoneal chemotherapy in ovarian cancer. Cancers (Basel). 2023;15(5):1402. https:\/\/doi.org\/10.3390\/cancers15051402.","journal-title":"Cancers (Basel)."},{"issue":"4","key":"14222_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ejso.2019.10.032","volume":"46","author":"SP Somashekhar","year":"2020","unstructured":"Somashekhar SP, Yethadka R, Kumar CR, Ashwin KR, Zaveri S, Rauthan A. Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies. Eur J Surg Oncol. 2020;46(4):577\u201381. https:\/\/doi.org\/10.1016\/j.ejso.2019.10.032.","journal-title":"Eur J Surg Oncol."},{"key":"14222_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejca.2019.10.034","volume":"127","author":"RC Auer","year":"2020","unstructured":"Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. Eur J Cancer. 2020;127:76\u201395. https:\/\/doi.org\/10.1016\/j.ejca.2019.10.034.","journal-title":"Eur J Cancer."},{"issue":"8","key":"14222_CR11","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s10434-999-0790-0","volume":"6","author":"AD Stephens","year":"1999","unstructured":"Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6(8):790\u20136. https:\/\/doi.org\/10.1007\/s10434-999-0790-0.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"14222_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/1477-7819-9-169","volume":"9","author":"TJ Cooksley","year":"2011","unstructured":"Cooksley TJ, Haji-Michael P. Post-operative critical care management of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC). World J Surg Oncol. 2011;9(1):169. https:\/\/doi.org\/10.1186\/1477-7819-9-169.","journal-title":"World J Surg Oncol."},{"issue":"8","key":"14222_CR13","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1245\/ASO.2003.01.018","volume":"10","author":"O Glehen","year":"2003","unstructured":"Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10(8):863\u20139. https:\/\/doi.org\/10.1245\/ASO.2003.01.018.","journal-title":"Ann Surg Oncol."},{"key":"14222_CR14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jss.2018.09.032","volume":"234","author":"F Gani","year":"2019","unstructured":"Gani F, Conca-Cheng AM, Nettles B, Ahuja N, Johnston FM. Trends in outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Surg Res. 2019;234:240\u20138. https:\/\/doi.org\/10.1016\/j.jss.2018.09.032.","journal-title":"J Surg Res."},{"issue":"2","key":"14222_CR15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/jamasurg.2013.3640","volume":"149","author":"MD Jafari","year":"2014","unstructured":"Jafari MD, Halabi WJ, Stamos MJ, et al. Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the american college of surgeons national surgical quality improvement program. JAMA Surg. 2014;149(2):170\u20135. https:\/\/doi.org\/10.1001\/jamasurg.2013.3640.","journal-title":"JAMA Surg."},{"issue":"6","key":"14222_CR16","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/SLA.0b013e3181a45d86","volume":"249","author":"TC Chua","year":"2009","unstructured":"Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: A systematic review of morbidity and mortality. Ann Surg. 2009;249(6):900\u20137. https:\/\/doi.org\/10.1097\/SLA.0b013e3181a45d86.","journal-title":"Ann Surg"},{"issue":"1","key":"14222_CR17","doi-asserted-by":"publisher","first-page":"e186847","DOI":"10.1001\/jamanetworkopen.2018.6847","volume":"2","author":"JM Foster","year":"2019","unstructured":"Foster JM, Sleightholm R, Patel A, et al. Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures. JAMA Netw Open. 2019;2(1):e186847. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.6847.","journal-title":"JAMA Netw Open."},{"issue":"3","key":"14222_CR18","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1001\/jamasurg.2016.4952","volume":"152","author":"O Ljungqvist","year":"2017","unstructured":"Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery: a review. JAMA Surg. 2017;152(3):292. https:\/\/doi.org\/10.1001\/jamasurg.2016.4952.","journal-title":"JAMA Surg."},{"issue":"1","key":"14222_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/bjs5.50238","volume":"4","author":"M Brindle","year":"2020","unstructured":"Brindle M, Nelson G, Lobo DN, Ljungqvist O, Gustafsson UO. Recommendations from the ERAS\u00ae Society for standards for the development of enhanced recovery after surgery guidelines. BJS Open. 2020;4(1):157\u201363. https:\/\/doi.org\/10.1002\/bjs5.50238.","journal-title":"BJS Open."},{"key":"14222_CR20","doi-asserted-by":"publisher","unstructured":"the impact of enhanced recovery protocol compliance on elective colorectal cancer resection: results from an international registry. Ann Surg. 2015;261(6):1153-1159. doi:https:\/\/doi.org\/10.1097\/SLA.0000000000001029","DOI":"10.1097\/SLA.0000000000001029"},{"key":"14222_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s40064-016-1793-5","volume":"5","author":"W Song","year":"2016","unstructured":"Song W, Wang K, Zhang R, Dai Q, Zou S. The enhanced recovery after surgery (ERAS) program in liver surgery: a meta-analysis of randomized controlled trials. Springerplus. 2016;5:207. https:\/\/doi.org\/10.1186\/s40064-016-1793-5.","journal-title":"Springerplus."},{"issue":"3","key":"14222_CR22","doi-asserted-by":"publisher","first-page":"237.e1","DOI":"10.1016\/j.ajog.2019.04.028","volume":"221","author":"L Wijk","year":"2019","unstructured":"Wijk L, Udumyan R, Pache B, et al. International validation of enhanced recovery after surgery society guidelines on enhanced recovery for gynecologic surgery. Am J Obst Gynecol. 2019;221(3):237.e1-11. https:\/\/doi.org\/10.1016\/j.ajog.2019.04.028.","journal-title":"Am J Obst Gynecol."},{"issue":"6","key":"14222_CR23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/ans.13538","volume":"86","author":"MDJ Stowers","year":"2016","unstructured":"Stowers MDJ, Manuopangai L, Hill AG, Gray JR, Coleman B, Munro JT. Enhanced recovery after surgery in elective hip and knee arthroplasty reduces length of hospital stay. ANZ J Surg. 2016;86(6):475\u20139. https:\/\/doi.org\/10.1111\/ans.13538.","journal-title":"ANZ J Surg."},{"key":"14222_CR24","doi-asserted-by":"publisher","unstructured":"Chicago Consensus Working Group, Plana A, Izquierdo FJ, et al. The chicago consensus on peritoneal surface malignancies: standards. Cancer. 2020;126(11):2516-2524. https:\/\/doi.org\/10.1002\/cncr.32825","DOI":"10.1002\/cncr.32825"},{"issue":"12","key":"14222_CR25","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ejso.2020.07.041","volume":"46","author":"M H\u00fcbner","year":"2020","unstructured":"H\u00fcbner M, Kusamura S, Villeneuve L, et al. Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS\u00ae) society recommendations \u2013 part i: preoperative and intraoperative management. Eur J Surg Oncol. 2020;46(12):2292\u2013310. https:\/\/doi.org\/10.1016\/j.ejso.2020.07.041.","journal-title":"Eur J Surg Oncol."},{"issue":"12","key":"14222_CR26","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1016\/j.ejso.2020.08.006","volume":"46","author":"M H\u00fcbner","year":"2020","unstructured":"H\u00fcbner M, Kusamura S, Villeneuve L, et al. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS\u00ae) Society Recommendations \u2013 Part II: Postoperative management and special considerations. Eur J Surg Oncol. 2020;46(12):2311\u201323. https:\/\/doi.org\/10.1016\/j.ejso.2020.08.006.","journal-title":"Eur J Surg Oncol."},{"issue":"5","key":"14222_CR27","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1002\/jso.26099","volume":"122","author":"OS Eng","year":"2020","unstructured":"Eng OS, Blakely AM, Lafaro KJ, et al. Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. J Surg Oncol. 2020;122(5):980\u20135. https:\/\/doi.org\/10.1002\/jso.26099.","journal-title":"J Surg Oncol."},{"issue":"4","key":"14222_CR28","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1245\/s10434-016-5692-3","volume":"24","author":"AH Maciver","year":"2017","unstructured":"Maciver AH, Al-Sukhni E, Esquivel J, Skitzki JJ, Kane JM, Francescutti VA. Current delivery of hyperthermic intraperitoneal chemotherapy with cytoreductive surgery (CS\/HIPEC) and perioperative practices: an international survey of high-volume surgeons. Ann Surg Oncol. 2017;24(4):923\u201330. https:\/\/doi.org\/10.1245\/s10434-016-5692-3.","journal-title":"Ann Surg Oncol."},{"issue":"12","key":"14222_CR29","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.1245\/s10434-021-09973-1","volume":"28","author":"A Dhiman","year":"2021","unstructured":"Dhiman A, Fenton E, Whitridge J, et al. Guide to enhanced recovery for cancer patients undergoing surgery: ERAS for patients undergoing cytoreductive surgery with or without HIPEC. Ann Surg Oncol. 2021;28(12):6955\u201364. https:\/\/doi.org\/10.1245\/s10434-021-09973-1.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"14222_CR30","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.surg.2015.01.016","volume":"157","author":"N Bakker","year":"2015","unstructured":"Bakker N, Cakir H, Doodeman HJ, Houdijk APJ. Eight years of experience with enhanced recovery after surgery in patients with colon cancer: Impact of measures to improve adherence. Surgery. 2015;157(6):1130\u20136. https:\/\/doi.org\/10.1016\/j.surg.2015.01.016.","journal-title":"Surgery."},{"issue":"13","key":"14222_CR31","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa012385","volume":"346","author":"D Bergqvist","year":"2002","unstructured":"Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. New Engl J Med. 2002;346(13):975\u201380. https:\/\/doi.org\/10.1056\/NEJMoa012385.","journal-title":"New Engl J Med."},{"issue":"1","key":"14222_CR32","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/02656736.2020.1795277","volume":"37","author":"N Laplace","year":"2020","unstructured":"Laplace N, Kepenekian V, Friggeri A, et al. Sodium thiosulfate protects from renal impairement following hyperthermic intraperitoneal chemotherapy (HIPEC) with Cisplatin. Int J Hyperthermia. 2020;37(1):897\u2013902. https:\/\/doi.org\/10.1080\/02656736.2020.1795277.","journal-title":"Int J Hyperthermia."},{"issue":"1","key":"14222_CR33","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12957-016-0892-7","volume":"14","author":"M Robella","year":"2016","unstructured":"Robella M, Vaira M, De Simone M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Oncol. 2016;14(1):128. https:\/\/doi.org\/10.1186\/s12957-016-0892-7.","journal-title":"World J Surg Oncol."},{"issue":"9","key":"14222_CR34","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.1245\/s10434-020-09476-5","volume":"28","author":"B White","year":"2021","unstructured":"White B, Dahdaleh F, Naffouje SA, et al. Impact of enhanced recovery after surgery on postoperative outcomes for patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2021;28(9):5265\u201372. https:\/\/doi.org\/10.1245\/s10434-020-09476-5.","journal-title":"Ann Surg Oncol."},{"key":"14222_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jss.2019.10.042","volume":"247","author":"PW Lu","year":"2020","unstructured":"Lu PW, Fields AC, Shabat G, et al. Cytoreductive surgery and HIPEC in an enhanced recovery after surgery program: a feasibility study. J Surg Res. 2020;247:59\u201365. https:\/\/doi.org\/10.1016\/j.jss.2019.10.042.","journal-title":"J Surg Res."},{"issue":"6","key":"14222_CR36","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.amjsurg.2019.06.019","volume":"219","author":"R Siddharthan","year":"2020","unstructured":"Siddharthan R, Dewey E, Billingsley K, Gilbert E, Tsikitis VL. Feasibility and benefits of an enhanced recovery after surgery protocol for patients undergoing cytoreductive surgery and heated intraperitoneal chemotharpy: a single institution experience. Am J Surg. 2020;219(6):1073\u20135. https:\/\/doi.org\/10.1016\/j.amjsurg.2019.06.019.","journal-title":"Am J Surg."},{"issue":"5","key":"14222_CR37","doi-asserted-by":"publisher","first-page":"331","DOI":"10.5455\/medarh.2019.73.331-337","volume":"73","author":"O Duzgun","year":"2019","unstructured":"Duzgun O. Evaluation of enhanced recovery after following a surgical protocol for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Med Arch. 2019;73(5):331. https:\/\/doi.org\/10.5455\/medarh.2019.73.331-337.","journal-title":"Med Arch."},{"issue":"1","key":"14222_CR38","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1245\/s10434-019-07900-z","volume":"27","author":"C Webb","year":"2020","unstructured":"Webb C, Day R, Velazco CS, et al. Implementation of an enhanced recovery after surgery (ERAS) program is associated with improved outcomes in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2020;27(1):303\u201312. https:\/\/doi.org\/10.1245\/s10434-019-07900-z.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"14222_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1515\/pp-2022-0133","volume":"8","author":"D Charleux-Muller","year":"2023","unstructured":"Charleux-Muller D, Fabacher T, Romain B, Meyer N, Brigand C, Delhorme JB. Implementation of an enhanced recovery program for complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a referral center: a case control prospective study. Pleura and Peritoneum. 2023;8(1):11\u20138. https:\/\/doi.org\/10.1515\/pp-2022-0133.","journal-title":"Pleura and Peritoneum."},{"issue":"2","key":"14222_CR40","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(20)30599-4.","journal-title":"Lancet Oncol."},{"key":"14222_CR41","doi-asserted-by":"publisher","first-page":"100653","DOI":"10.1016\/j.ctarc.2022.100653","volume":"33","author":"H Elgendy","year":"2022","unstructured":"Elgendy H, Iqbal M, Youssef T, Alzahrani A, Rugaan A. Optimizing risk factors influence intensive care stay after hyperthermic intraperitoneal chemotherapy? an observational cohort study. Cancer Treatment Res Commun. 2022;33:100653. https:\/\/doi.org\/10.1016\/j.ctarc.2022.100653.","journal-title":"Cancer Treatment Res Commun."},{"issue":"2","key":"14222_CR42","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/j.semtcvs.2020.02.029","volume":"32","author":"R Salenger","year":"2020","unstructured":"Salenger R, Morton-Bailey V, Grant M, Gregory A, Williams JB, Engelman DT. Cardiac enhanced recovery after surgery: a guide to team building and successful implementation. Sem Thoracic Cardiovasc Surg. 2020;32(2):187\u201396. https:\/\/doi.org\/10.1053\/j.semtcvs.2020.02.029.","journal-title":"Sem Thoracic Cardiovasc Surg"},{"issue":"6","key":"14222_CR43","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.suc.2018.07.001","volume":"98","author":"JY Liu","year":"2018","unstructured":"Liu JY, Wick EC. Enhanced recovery after surgery and effects on quality metrics. Surg Clin North America. 2018;98(6):1119\u201327. https:\/\/doi.org\/10.1016\/j.suc.2018.07.001.","journal-title":"Surg Clin North America."},{"issue":"5","key":"14222_CR44","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/archsurg.2010.309","volume":"146","author":"UO Gustafsson","year":"2011","unstructured":"Gustafsson UO. Adherence to the enhanced recovery after surgery protocol and outcomes after colorectal cancer surgery. Arch Surg. 2011;146(5):571. https:\/\/doi.org\/10.1001\/archsurg.2010.309.","journal-title":"Arch Surg."},{"issue":"9","key":"14222_CR45","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.1463-1318.2011.02856.x","volume":"14","author":"J Ahmed","year":"2012","unstructured":"Ahmed J, Khan S, Lim M, Chandrasekaran TV, MacFie J. Enhanced recovery after surgery protocols \u2013 compliance and variations in practice during routine colorectal surgery. Colorectal Disease. 2012;14(9):1045\u201351. https:\/\/doi.org\/10.1111\/j.1463-1318.2011.02856.x.","journal-title":"Colorectal Disease."},{"issue":"7","key":"14222_CR46","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00268-016-3460-y","volume":"40","author":"UO Gustafsson","year":"2016","unstructured":"Gustafsson UO, Oppelstrup H, Thorell A, Nygren J, Ljungqvist O. Adherence to the ERAS protocol is Associated with 5-Year survival after colorectal cancer surgery: a retrospective cohort study. World J Surg. 2016;40(7):1741\u20137. https:\/\/doi.org\/10.1007\/s00268-016-3460-y.","journal-title":"World J Surg."},{"issue":"8","key":"14222_CR47","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1001\/jamasurg.2019.0995","volume":"154","author":"J Ripoll\u00e9s-Melchor","year":"2019","unstructured":"Ripoll\u00e9s-Melchor J, Ram\u00edrez-Rodr\u00edguez JM, Casans-Franc\u00e9s R, et al. Association between use of enhanced recovery after surgery protocol and postoperative complications in colorectal surgery: the postoperative outcomes within enhanced recovery after surgery Protocol (POWER) Study. JAMA Surg. 2019;154(8):725\u201336. https:\/\/doi.org\/10.1001\/jamasurg.2019.0995.","journal-title":"JAMA Surg."},{"issue":"11","key":"14222_CR48","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1007\/s00432-021-03891-1","volume":"148","author":"J Feng","year":"2022","unstructured":"Feng J, Li K, Xu R, et al. Association between compliance with enhanced recovery after surgery (ERAS) protocols and postoperative outcome in patients with primary liver cancer undergoing hepatic resection. J Cancer Res Clin Oncol. 2022;148(11):3047\u201359. https:\/\/doi.org\/10.1007\/s00432-021-03891-1.","journal-title":"J Cancer Res Clin Oncol."},{"issue":"1","key":"14222_CR49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.21037\/hbsn-21-294","volume":"12","author":"M Schmelzle","year":"2023","unstructured":"Schmelzle M, Krenzien F, Dahlke P, et al. Validation of the enhanced recovery after surgery (ERAS) society recommendations for liver surgery: a prospective, observational study. Hepatobiliary Surg Nutr. 2023;12(1):20\u201336. https:\/\/doi.org\/10.21037\/hbsn-21-294.","journal-title":"Hepatobiliary Surg Nutr."},{"issue":"8","key":"14222_CR50","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/s00268-020-05499-x","volume":"44","author":"D Roulin","year":"2020","unstructured":"Roulin D, Melloul E, Wellg BE, et al. Feasibility of an enhanced recovery protocol for elective pancreatoduodenectomy: a multicenter international cohort study. World J Surg. 2020;44(8):2761\u20139. https:\/\/doi.org\/10.1007\/s00268-020-05499-x.","journal-title":"World J Surg."},{"issue":"10","key":"14222_CR51","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1477-2574.2012.00521.x","volume":"14","author":"N Robertson","year":"2012","unstructured":"Robertson N, Gallacher PJ, Peel N, et al. Implementation of an enhanced recovery programme following pancreaticoduodenectomy. HPB. 2012;14(10):700\u20138. https:\/\/doi.org\/10.1111\/j.1477-2574.2012.00521.x.","journal-title":"HPB."},{"issue":"11","key":"14222_CR52","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1007\/s00268-014-2653-5","volume":"38","author":"M Braga","year":"2014","unstructured":"Braga M, Pecorelli N, Ariotti R, et al. Enhanced recovery after surgery pathway in patients undergoing pancreaticoduodenectomy. World J Surg. 2014;38(11):2960\u20136. https:\/\/doi.org\/10.1007\/s00268-014-2653-5.","journal-title":"World J Surg."},{"key":"14222_CR53","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ijsu.2016.11.088","volume":"36","author":"M Pisarska","year":"2016","unstructured":"Pisarska M, P\u0119dziwiatr M, Ma\u0142czak P, et al. Do we really need the full compliance with ERAS protocol in laparoscopic colorectal surgery? A prospective cohort study. Int J Surg. 2016;36:377\u201382. https:\/\/doi.org\/10.1016\/j.ijsu.2016.11.088.","journal-title":"Int J Surg."},{"issue":"3","key":"14222_CR54","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000450685","volume":"34","author":"D Roulin","year":"2017","unstructured":"Roulin D, Muradbegovic M, Addor V, Blanc C, Demartines N, H\u00fcbner M. Enhanced recovery after elective colorectal surgery \u2013 reasons for non-compliance with the protocol. Dig Surg. 2017;34(3):220\u20136. https:\/\/doi.org\/10.1159\/000450685.","journal-title":"Dig Surg."},{"issue":"2","key":"14222_CR55","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/jgh3.12250","volume":"4","author":"J Philip","year":"2020","unstructured":"Philip J, Fairtile R, Cocieru A. Postoperative complications are main reason for noncompliance with enhanced recovery after surgery program in patients undergoing hepatectomy and pancreatectomy. JGH Open. 2020;4(2):236\u201340. https:\/\/doi.org\/10.1002\/jgh3.12250.","journal-title":"JGH Open."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14222-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-14222-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14222-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T15:10:19Z","timestamp":1699197019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-14222-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":55,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["14222"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-14222-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]},"assertion":[{"value":"5 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Beatrice J. Sun, Tiffany M. Yue, Nova Xu, Cedar Fowler, and Byrne Lee have no disclosures to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}